norethindrone, ethinyl estradiol, and ferrous fumarate
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (norethindrone, ethinyl estradiol, and ferrous fumarate) by Teva is ovulation. First approved in 2010.
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
Norethindrone and ethinyl estradiol and ferrous fumarate is an oral contraceptive combination tablet that prevents ovulation through hormonal suppression. The formulation includes ferrous fumarate in the placebo tablets to provide iron supplementation during the pill-free interval. This chewable tablet option offers convenience for patients seeking flexible dosing.
Product approaching loss of exclusivity with moderate competitive pressure; expect transition focus toward lifecycle management and generic preparation rather than growth initiatives.
ovulation.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With zero linked job postings and approaching LOE status, this product represents a late-stage career opportunity rather than a growth platform. Roles focus on defensive market management, generic transition planning, and regulatory compliance rather than innovation or expansion.
Worked on NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.